Keywords
Anti-neuronal antibody
Treatment
Submitted : 2024-08-10
Accepted : 2024-08-25
Published : 2024-09-09
Abstract
Autoimmune encephalitis (AE) can arise from various etiologies and present with complex clinical manifestations, especially in cases involving multiple anti-neuronal antibodies. This report presents two cases of AE with multiple anti-neuronal antibodies admitted to Ningbo Medical Center Li Huili Hospital on October 9, 2020, and March 12, 2024. Case 1 is a 15-year-old boy with positive anti-N-methyl-D-aspartate receptor (NMDAR) and anti-metabotropic glutamate receptor 5 (mGluR5) antibodies in his serum and cerebrospinal fluid (CSF). Case 2 is a 14-year-old boy with positive NMDAR and myelin oligodendrocyte glycoprotein (MOG) antibodies in his CSF. Patients with AE who have multiple anti-neuronal antibodies present significant diagnostic and therapeutic challenges, warranting close clinical attention.
References
Granerod J, Ambrose HE, Davies NW, et al., 2010, Causes of Encephalitis and Differences in Their Clinical Presentations in England: A Multicentre, Population-Based Prospective Study. Lancet Infect Dis, 10(12): 835–844. https://doi.org/10.1016/S1473-3099(10)70222-X
Wang JD, Xie L, Fang X, et al., 2022, [Clinical Validation of the 2020 Diagnostic Approach for Pediatric Autoimmune Encephalitis in a Single Center]. Zhonghua Er Ke Za Zhi, 60(8): 786–791. https://doi.org/10.3760/cma.j.cn112140-20220111-00039
Yeshokumar AK, Coughlin A, Fastman J, et al., 2021, Seizures in Autoimmune Encephalitis – A Systematic Review and Quantitative Synthesis. Epilepsia, 62(2): 397–407. https://doi.org/10.1111/epi.16807
Petit-Pedrol M, Armangue T, Peng X, et al., 2014, Encephalitis with Refractory Seizures, Status Epilepticus, and Antibodies to the GABAA Receptor: A Case Series, Characterisation of the Antigen, and Analysis of the Effects of Antibodies, Lancet Neurol, 13(3): 276–286. https://doi.org/10.1016/s1474-4422(13)70299-0
Lin Z, Zhou F, Ni L, et al., 2024, Case Report: Successful Treatment of An Anti-D2R and DPPX Antibody-Associated Autoimmune Encephalitis Patient with High-Dose Methylprednisolone and Intravenous Immunoglobulin. Front Immunol, 15: 1338714. https://doi.org/10.3389/fimmu.2024.1338714
Zhao J, Wang C, Xu X, et al., 2019, Coexistence of Autoimmune Encephalitis and Other Systemic Autoimmune Diseases. Front Neurol, 10: 1142. https://doi.org/10.3389/fneur.2019.01142
Nissen MS, Ryding M, Meyer M, et al., 2020, Autoimmune Encephalitis: Current Knowledge on Subtypes, Disease Mechanisms and Treatment. CNS Neurol Disord Drug Targets, 19(8): 584–598. https://doi.org/10.2174/1871527319666200708133103
Alexopoulos H, Dalakas MC, 2019, The Immunobiology of Autoimmune Encephalitides. J Autoimmun, 104: 102339. https://doi.org/10.1016/j.jaut.2019.102339
Zhu S, Yu J, Wu Y, et al., 2022, Pathophysiology and Clinical Management of Autoimmune Encephalitis-Associated Seizures. Neuroimmunomodulation, 29(4): 282–295. https://doi.org/10.1159/000524783
Al-Diwani A, Pollak TA, Langford AE, et al., 2017, Synaptic and Neuronal Autoantibody-Associated Psychiatric Syndromes: Controversies and Hypotheses. Front Psychiatry, 8: 13. https://doi.org/10.3389/fpsyt.2017.00013
Titulaer MJ, McCracken L, Gabilondo I, et al., 2013, Treatment and Prognostic Factors for Long-Term Outcome in Patients with Anti-NMDA Receptor Encephalitis: An Observational Cohort Study. Lancet Neurol, 12(2): 157–165. https://doi.org/10.1016/S1474-4422(12)70310-1
Yan W, Mengke W, Zhiqiang S, et al., 2024, Clinical Features, Cerebrospinal Fluid Changes, and Prognosis in Chinese Patients with Autoimmune Encephalitis. Acta Neurol Belg, preprint. https://doi.org/10.1007/s13760-024-02537-6
Hayden Z, Bóné B, Orsi G, et al., 2021, Clinical Characteristics and Outcome of Neuronal Surface Antibody-Mediated Autoimmune Encephalitis Patients in a National Cohort. Front Neurol, 12: 611597. https://doi.org/10.3389/fneur.2021.611597
Masciocchi S, Businaro P, Scaranzin S, et al., 2024, General Features, Pathogenesis, and Laboratory Diagnostics of Autoimmune Encephalitis. Crit Rev Clin Lab Sci, 61(1): 45–69. https://doi.org/10.1080/10408363.2023.2247482
Baumgartner A, Rauer S, Hottenrott T, et al., 2019, Admission Diagnoses of Patients Later Diagnosed with Autoimmune Encephalitis. J Neurol, 266(1): 124–132. https://doi.org/10.1007/s00415-018-9105-3
Endres D, Maier V, Leypoldt F, et al., 2022, Autoantibody-Associated Psychiatric Syndromes: A Systematic Literature Review Resulting in 145 Cases. Psychol Med, 52(6): 1135–1146. https://doi.org/10.1017/S0033291720002895
Chekanova EO, Shabalina AA, Zakharova MN, 2023, Klinicheskie Kharakteristiki i Kratkosrochnye Iskhody Autoimmunnogo Entsefalita u Vzroslykh [Clinical Characteristics and Short-Term Outcomes of Autoimmune Encephalitis in Adults]. Zh Nevrol Psikhiatr Im S S Korsakova, 123(7. Vyp. 2): 103–115. https://doi.org/10.17116/jnevro2023123072103
Liao D, Zhong L, Yang L, et al., 2023, Clinical and Radiological Features, Treatment Responses and Prognosis in Pediatric Patients with Co-Existing Anti-N-Methyl-D-Aspartate Receptor and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Encephalitis: A Single Center Study. Mult Scler Relat Disord, 81: 105133. https://doi.org/10.1016/j.msard.2023.105133
Wu Q, Xie Q, Liu L, et al., 2023, Factors Influencing Prognosis and Relapse in Patients with Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Mult Scler Relat Disord, 74: 104697. https://doi.org/10.1016/j.msard.2023.104697
Zhou Y, Chen H, Zhu M, et al., 2024, Clinical Characteristics of Autoimmune Encephalitis with Co-Existence of Multiple Anti-Neuronal Antibodies. BMC Neurol, 24(1): 1. https://doi.org/10.1186/s12883-023-03514-x
Cafalli C, Amorim E, Silva F, et al., 2020, Autoimmune Encephalitis (AIE). Rev Assoc Med Bras (1992), 66(9): 1172–1178. https://doi.org/10.1590/1806-9282.66.7.1172
Thaler FS, Zimmermann L, Kammermeier S, et al., 2021, Rituximab Treatment and Long-term Outcome of Patients with Autoimmune Encephalitis: Real-world Evidence from the GENERATE Registry. Neurol Neuroimmunol Neuroinflamm, 8(6): e1088. https://doi.org/10.1212/NXI.000000000000108
Zhou Q, Yin D, Ma J, et al., 2023, The Therapeutic Effect of Ofatumumab in Autoimmune Encephalitis: A Case Series. J Neuroimmunol, 377: 578062. https://doi.org/10.1016/j.jneuroim.2023.578062
Kang Q, Liao H, Yang L, et al., 2022, Clinical Characteristics and Short-Term Prognosis of Children with Antibody-Mediated Autoimmune Encephalitis: A Single-Center Cohort Study. Front Pediatr, 10: 880693. https://doi.org/10.3389/fped.2022.880693
Wang B, Wang C, Feng J, et al., 2022, Clinical Features, Treatment, and Prognostic Factors in Neuronal Surface Antibody-Mediated Severe Autoimmune Encephalitis. Front Immunol, 13: 890656. https://doi.org/10.3389/fimmu.2022.890656
Nepal G, Shing YK, Yadav JK, et al., 2020, Efficacy and Safety of Rituximab in Autoimmune Encephalitis: A Meta-Analysis. Acta Neurol Scand, 142(5): 449–459. https://doi.org/10.1111/ane.13291
Shang H, Shen X, Yu X, et al., 2024, B-cell Targeted Therapies in Autoimmune Encephalitis: Mechanisms, Clinical Applications, and Therapeutic Potential. Front Immunol, 15: 1368275. https://doi.org/10.3389/fimmu.2024.1368275
Qiao S, Zhang SC, Wang ZH, et al., 2022, Coexistence of Multiple Anti-Neuronal Antibodies in Autoimmune Encephalitis in China: A Multi-Center Study. Front Immunol, 13: 858766. https://doi.org/10.3389/fimmu.2022.858766
Dalmau J, Geis C, Graus F, 2017, Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System. Physiol Rev, 97(2): 839–887. https://doi.org/10.1152/physrev.00010.2016
Ryding M, Mikkelsen AW, Nissen MS, et al., 2023, Pathophysiological Effects of Autoantibodies in Autoimmune Encephalitides. Cells, 13(1): 15. https://doi.org/10.3390/cells13010015